Oil fell, and the Nasdaq hit a new record today before reversing into the close. Earnings kept delivering the season’s most dramatic individual moves right alongside a catastrophic guidance cut from GeneDx.
Today’s edition has every name worth knowing.
Don’t ignore this (Sponsored)
There's one strange household item that has predicted every major recession in the United States since 1929.
It's not a stock. It's not a bond. It's not anything your financial advisor has ever mentioned.
It just triggered again. For the first time since 2008.
And it's one of 7 underground economic signals all flashing red at the same time right now.
A free report called "The Bellwether Signal" from American Alternative Assets reveals what the item is, what all 7 signals are, and a simple strategy to protect your retirement before history repeats.
Get Your Free Report
Elite Trade Club Insider
One Energy Insider Sold Near The Highs. One Shipping Insider Kept Buying.
A director at an oilfield services name sold more than $4.6 million after the stock more than doubled over the past year, while a maritime insider bought shares across three straight sessions near the stock’s own 52-week high.
Most readers will see two commodity-linked stocks. Insider readers will see the split between harvesting a huge run and still adding capital near strength.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money-back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Markets
Oil fell after Defense Secretary Hegseth confirmed the ceasefire holds and two U.S. commercial ships safely transited the Strait of Hormuz with destroyer escort, the first successful commercial passage since the war began, while WTI dropped toward $102 and Brent slipped to above $110.
Earnings kept driving individual moves, with roughly 85% of S&P 500 companies beating estimates and DuPont and AB InBev both surging on strong quarterly results.
Gas prices hit $4.48 per gallon nationally, the highest since July 2022, and JPMorgan warned that if the conflict drags into June, crude could push toward $150 per barrel.
Coinbase confirmed it is cutting 14% of its workforce ahead of Thursday's earnings, while GameStop’s unsolicited bid for eBay prompted Michael Burry to publicly dump his entire GameStop position.
Market-Moving News
Automotive
A Key Growth Plan Is Facing Pushback at the Worst Time
Tesla (NASDAQ: TSLA) is facing a major challenge in Europe as regulators raise serious concerns about its Full Self-Driving system. Officials across multiple countries have questioned safety, performance, and how the technology is presented to drivers, slowing down progress toward broader approval.
This creates a significant hurdle in a region where Tesla is trying to regain momentum. The situation matters because Europe is not a small market. It is a critical piece of Tesla’s global growth strategy, especially after recent declines in sales across the region.
A Growth Plan Faces Resistance
Tesla has been pushing hard to expand its presence in Europe. Approval of its driving system plays a central role in that plan, helping differentiate its vehicles and unlock new revenue streams. You now have a company facing resistance at a point where execution matters most.
Pressure on the Bigger Strategy
The concerns raised by regulators go beyond technical details. They reflect deeper hesitation about safety standards and how the system is used in real-world conditions. That creates friction between Tesla’s approach and European expectations.
Tesla is now in a position where regulatory approval becomes a major factor in its next phase. The stakes are higher now. You begin to see Tesla not just as a fast-moving innovator, but as a company that has to align its ambitions with how different markets operate.
Pharma
CVS Just Made a Big Call That Shakes a Billion-Dollar Drug Market
CVS Health (NYSE: CVS) just made a major shift that goes far beyond one drug. The company will start prioritizing lower-cost biosimilar treatments over Johnson & Johnson’s blockbuster drug Stelara across its key drug lists starting in July.
That decision directly affects how millions of patients access treatment and how pharmaceutical companies compete for coverage. It changes who gets preferred access in one of the most influential parts of the healthcare system.
A Gatekeeper Just Changed the Game
CVS controls what drugs are easier to access through its pharmacy benefit system. When it shifts preference, it immediately impacts demand across the market. You now have a situation where lower-cost alternatives move to the front, while a major-brand drug is pushed back.
That kind of move sends a strong signal. It shows that cost and accessibility are becoming the deciding factors, not just brand dominance.
Stelara has been one of Johnson & Johnson’s most important products. Losing preferred positioning puts pressure on how long it can maintain its dominance in the market. At the same time, biosimilar makers gain a major opening to scale faster.
What This Sets Up Next
This decision does not stay isolated. Other healthcare players often follow similar strategies once a shift like this proves effective. That creates a ripple effect across multiple drug categories.
The direction is becoming clear. You are entering a market where pricing power shifts toward lower-cost alternatives, changing how pharmaceutical companies compete at scale.
Cell Therapy (Sponsored)
A longevity-focused biotech company has started GMP production for its Master Cell Bank in partnership with Austrianova, supporting its α-Klotho anti-aging program.
This step may help build the infrastructure needed for future cell-based therapeutic development in areas tied to aging, metabolic health, and chronic disease.
Early-stage biotech carries risk, but for readers following longevity and regenerative medicine, this is a development worth watching.
Read more about this longevity biotech update.
Partnerships
This Moment Signals a Real Comeback Story
Intel (NASDAQ: INTC) just hit a major turning point as reports emerge that Apple is exploring using its chips for devices manufactured in the United States. This development puts Intel back into one of the industry's most important supply chains, marking a clear shift in how the company is positioned today.
The significance goes beyond a single partnership. Apple has long relied on other suppliers, so even being considered signals a change in confidence around Intel's capabilities.
Back at the Highest Level
Intel has spent years trying to regain its footing. Being part of discussions with a company like Apple shows that it is once again relevant in conversations that define the industry.
You get a company moving from recovery mode into real competition. That shift changes perception fast. It puts Intel back among the key players shaping major decisions.
A Comeback That Feels Real
Intel has been building momentum through partnerships and investments. This potential deal adds credibility to that progress, showing that the company's efforts are starting to translate into meaningful opportunities.
This is where things become clearer. Your understanding of Intel moves from a company trying to catch up to one actively rebuilding its position.
Being part of a major supply chain creates long-term impact. It leads to deeper relationships, follow-on opportunities, and stronger positioning across the industry.
The direction is now taking shape. Intel is not just a recovering company, but one that is re-entering the highest level of competition with momentum behind it.
Top Winners and Losers
EverQuote [EVER] $23.82 (+63.04%)
EverQuote’s AI-powered insurance marketplace delivered Q1 revenue of $190.9 million, up 15% year-over-year and ahead of estimates, with record Adjusted EBITDA of $29.3 million, up 30%, and a Q2 guide implying 21% growth.
The company holds $178.5 million in cash, carries zero debt, and is on a clear path to $1 billion in annual revenue. Three consecutive quarters of annualized EBITDA above $100 million made the case for you.
Sterling Infrastructure [STRL] $806.00 (+52.22%)
Sterling Infrastructure beat Q1 revenue estimates by 41%, the largest revenue surprise of earnings season, as AI data center construction, transportation infrastructure, and e-infrastructure projects all came in well ahead of expectations.
Management raised full-year guidance to match. The company is up 74% year-to-date, and the AI infrastructure buildout is turning it into one of the season’s clearest earnings story stocks.
DigitalOcean [DOCN] $152.77 (+40.40%)
DigitalOcean reported Q1 revenue of $258 million, up 22% year-over-year, with AI customer ARR growing 221% and customers spending over $1 million annually growing 179%.
The company launched its AI native cloud platform, earned a top benchmark ranking for open-source model output speed, and raised full-year guidance. When AI revenue triples and guidance goes up, the stock tends to follow.
GeneDx [WGS] $34.51 (-49.22%)
GeneDx missed Q1 revenue estimates by 10% at $102.3 million, took a $31.3 million non-cash impairment on its Fabric unit, and cut full-year revenue guidance from roughly $545 million to $475-490 million.
Volume actually grew 34%, but a faster-than-expected shift to lower-priced genome testing crushed revenue per test. Growing volume but shrinking revenue is a difficult story to tell on an earnings call.
BellRing Brands [BRBR] $10.63 (-38.77%)
BellRing reported adjusted EPS of $0.14 against a $0.31 estimate and adjusted EBITDA that missed by 32%, with gross margin collapsing to 27% from 32% a year earlier on an ingredient quality charge, input cost inflation, and a brutal promotional environment in the protein shake category.
Management cut full-year guidance to flat revenue growth. Protein shakes are not supposed to be this complicated.
Aviat Networks [AVNW] $15.09 (-33.35%)
Aviat delivered significant margin compression and a deepening operating loss as North American Tier 1 carrier weakness and acquisition integration costs from Pasolink and 4RF ran ahead of revenue. Management cut full-year guidance.
The $200 million Strong Buy-rated company is absorbing two acquisitions simultaneously while its biggest customer segment slows, and Tuesday’s results showed exactly what that tension looks like in an earnings report.
What's the most counterintuitive thing the market has taught you personally?
Top Picks (Sponsored)
Only a tiny percentage of stocks meet the criteria for this report.
Analysts have released a new edition highlighting seven names selected using multiple indicators.
Recent picks have delivered notable short-term gains, though results can vary.
The latest report is now available for a limited time.
Download the free report today
Everything Else
📘 Small-cap momentum is starting to build, as a select group of under-the-radar names across AI, energy, and emerging tech begin flashing the kind of early signals that can precede a larger move.
📚 Major publishers are suing Meta over copyright infringement in AI training, because feeding someone else's books into your model tends to come with a legal bill eventually.
💊 The White House says a new drug pricing deal will save $64.3 billion over ten years, which sounds impressive until you remember how much Americans spend on prescriptions in a single year.
📈 Wall Street marched higher as US–Iran tensions cooled, giving traders the kind of exhale that doubles as a buying signal.
🔋 Ford's secret EV unit is quietly pushing forward despite the broader market slowdown, proving that sometimes the best strategy is just not quitting.
🎮 GameStop's $56 billion pursuit of eBay is lighting up social media, because if there's one company that knows how to turn a headline into a meme, it's this one.
That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
